A Small Molecule (Pluripotin) as a Tool for Studying Cancer Stem Cell Biology: Proof of Concept

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Mertins, Susan D ^a   Scudiero, Dominic A ^b   Hollingshead, Melinda G ^a   Divelbiss, Raymond D ^a   Alley, Michael C ^a   Monks, Anne ^b   Covell, David G ^a   Hite, Karen M ^b   Salomon, David S ^c   Niederhuber, John E ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CD133 ANTIGEN; ENZYME INHIBITOR; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OCTAMER TRANSCRIPTION FACTOR 4; PLURIPOTIN; S6 KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER RESEARCH; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; CELL COUNT; CELL STRAIN HCT116; CELL STRAIN HT29; CELL SURVIVAL; CELLULAR PARAMETERS; CLONOGENESIS; COLON CANCER; COLONY FORMATION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEASIBILITY STUDY; FEMALE; IN VITRO STUDY; INTRACELLULAR SIGNALING; MOLECULAR DYNAMICS; MOLECULAR PROBE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPHERE FORMATION; TUMOR VOLUME; VALIDATION STUDY;

EID: 84874306180     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057099     Document Type: Article

References (42)

1. Visvader JE, (2011) Cells of origin in cancer. Nature 469: 314-322.
2. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, et al. (2006) Cancer stem cells- Perspectives on current status and future directions: AACR workshop on Cancer Stem Cells. Cancer Res 66: 9339-9344.
3. Dick JE, (2008) Stem cell concepts renew cancer research. Blood 112: 4793-4807.
4. Borovski T, Melo FDSE, Vermeulen L, Medema JP, (2011) Cancer stem cell niche: The place to be. Cancer Res 71: 634-639.
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988.
6. O'Brien CA, Pollett A, Gallinger S, Dick JE, (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
7. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, et al. (2008) Efficient tumour formation by single human melanoma cells. Nature 456: 593-598.
8. Rappa G, Mercapide J, Anzanello F, Prasmickaite L, Xi Y, et al. (2008) Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. Exp Cell Res 314: 2110-2122.
9. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ, (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951.
10. Alkatout I, Kabelitz D, Kalthoff H, Tiwari S, (2008) Prowling wolves in sheep's clothing: the search for tumor stem cells. Biol Chem 389: 799-811.
11. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, et al. (2011) Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146: 633-644.
12. Chen S, Do JT, Zhang Z, Yao S, Yan F, et al. (2006) Self-renewal of embryonic stem cells by a small molecule. Proc Natl Acad Sci USA 103: 17266-17271.
13. Lee J, Kotilarova S, Kotliarova Y, Li A, Sun Q, et al. (2006) Tumor stem cells derived from gliobastomas cultured in bFGF and EGF closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391-403.
14. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
15. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL, (2008) CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Brit J Can 98: 756-765.
16. Ma S, Chan KW, Hu L, Lee TK, Wo JY, et al. (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556.
17. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, et al. (2006) Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Comm 351: 820-824.
18. Vermeulen L, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, et al. (2008) Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA 105: 13427-13432.
19. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke ME, et al. (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253-1270.
20. Moraes RC, Zhang X, Harrington N, Fung JY, Wu MF, et al. (2007) Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development 134: 1231-1242.
21. Hurt EM, Chan K, Serrat MA, Thomas SB, Veenstra TD, et al. (2010) Identification of vitronectin as an extrinsic inducer of cancer stem cell differentiation and tumor formation. Stem Cells 28: 461-470.
22. Pastrana E, Silva-Vargas V, Doetsch F, (2011) Eyes Wide Open: A critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 8: 486-498.
23. Chambers I, Tomlinson SR, (2009) The transcriptional foundation of pluripotency. Development 136: 2311-2322.
24. Huang R, Wallqvist A, Covell DG, (2006) Comprehensive analysis of pathway or functionally related gene expression in the National Cancer Institute's anticancer screen. Genomics 87: 315-328.
25. Huang R, Wallqvist A, Covell DG, (2006) Targeting changes in cancer: Assessing pathway stability by comparing pathway gene expression coherence levels in tumor and normal tissues. Mol Cancer Ther 5: 2417-2427.
26. Anjum R, Blenis J, (2008) The RSK family of kinases: Emerging roles in cellular signalling. Nat Rev Mol Cell Biol 9: 747-758.
27. Okram B, Nagle A, Adrian FJ, Lee C, Ren P, et al. (2006) A general strategy for creating "inactive-conformation" Abl inhibitors. Chem Biol 13: 779-786.
28. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, et al. (2005) Identification of the first specific inhibitor of p90 Ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res 65: 1027-1034.
29. Leder K, Holland EC, Michor F, (2010) The therapeutic implications of plasticity of the cancer stem cell phenotype. PLoS One 5: e14366.
30. Kirkland SC, Ying H, (2008) Alpha2ß1 integrin regulates lineage commitment in multipotent human colorectal cancer cells. J Biol Chem 283: 27612-27619.
31. Pontier SM, Muller WJ, (2009) Integrins in mammary-stem-cell biology and breast-cancer progression-a role in cancer stem cells? J Cell Sci 122: 207-214.
32. Jaggupilli A, Elkord E, (2012) Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol 2012: 1-11.
33. Magee JA, Piskonova E, Morrison SJ, (2012) Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer Cell 21: 283-296.
34. Brabletz T, (2012) EMT and MET in metastasis: Where are the cancer stem cells? Cancer Cell 22: 699-701.
35. Kriegsheim Av, Baiocchi D, Birtwistle M, Sumpton D, Bienvenut W, et al. (2009) Cell fate decisions are specified by the dynamic ERK interactome. Nat Cell Biol 11: 1458-1466.
36. Lorenzi PL, Reinhold WC, Varma S, Hutchinson AA, Pommier Y, et al. (2009) DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther 8: 713-724.
37. Alley MC, Pacula-Cox CM, Hursey ML, Rubinstein LR, Boyd MR, (1991) Morphometric and colorimetric analyses of human tumor cell line growth and drug sensitivity in soft agar culture. Cancer Res 51: 1247-1256.
38. Plowman J, Dykes DJ, Hollingshead M, Simpson-Herren L, Alley MC, editors (1997) Human tumor xenograft models in NCI Drug Development. Totowa, NJ: Human Press. 101-125 p.
39. Gamelin E, Mertins SD, Regis JT, Mickley L, Abati A, et al. (1999) Intrinsic drug resistance in primary and metastatic renal cell carcinoma. J Urol 162: 217-224.
40. Nguyen TL, Gussio R, Smith JA, Lannigan DA, Hecht SM, et al. (2006) Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore. Bioorg Med Chem 14: 6097-6105.
41. Horiuchi KY, Wang Y, Diamond SL, Ma H, (2006) Microarrays for the functional analysis of the chemical-kinase interactome. J Biomol Screen 11: 48-56.
42. Taswell C, (1981) Limiting dilution assays for the determination of immunocompetent cells frequencies I. Data analysis. J Immunol 126: 1614-1619.